

# Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy

Alex Aleshin<sup>1</sup> and Peter L. Greenberg<sup>1,2</sup>

<sup>1</sup>Stanford University Cancer Center, Stanford, CA; and <sup>2</sup>Stanford Cancer Institute, Stanford, CA


The clinical heterogeneity of the myelodysplastic syndromes (MDSs) relates to the recently discerned panoply of molecular abnormalities extant within this disease spectrum. Despite increasing recognition of these biologic abnormalities, very limited therapeutic options exist to exploit our increasing understanding of the molecular pathophysiology of MDS, with only 1 therapy (lenalidomide) particularly focused on a specific clinical patient subset (del(5q) cytogenetics) and 2 epigenetic modulators (azacitidine and decitabine) having been approved for treating these patients. This article will review the mutational and biologic landscape of these disorders, as well as the targeted therapeutics currently in clinical trials that are focused on attacking these features. Given the molecular complexity of these disorders and the limited repertoire of effective therapeutic agents, we will also discuss novel approaches attempting to determine potentially effective and personalized treatment options through complementary chemosensitivity and computerized signaling network screening for these disparate MDS patient subsets. Translational use of such resources, combined with the rapidly evolving next-generation molecular technologies, should prove useful in effectuating improved and more selective options for therapy.

## Introduction

The myelodysplastic syndromes (MDSs) are a heterogeneous spectrum of chronic myeloid hemopathies with associated symptomatic cytopenias and substantial potential for evolution to acute myeloid leukemia (AML).<sup>1,2</sup> Clinical characterization has demonstrated these patients to be within diverse prognostic risk groups, necessitating differing treatment strategies.<sup>1</sup> Only 3 drugs are approved by the US Food and Drug Administration (FDA) for treating this group of disorders, with none approved in the past decade. The hypomethylating agents (HMAs) azacitidine and decitabine have response rates ~40% for higher-risk (HR) patients, and lenalidomide has a response rate of 60% to 70% for del(5q) patients and 20% to 30% for non-(del5q) patients.<sup>3-6</sup> However, given the substantial proportion of MDS patients whose disease is unresponsive to treatment or relapses following initial response, clinical trials with new and effective drugs are urgently needed.

Much of the difficulty in treating these patients relates to their biologic heterogeneity, with the patients having a cohort of disparate cytogenetic and myeloid cell mutational profiles.<sup>7</sup> During the past decade, major strides have occurred in the molecular characterization of MDSs.<sup>8-11</sup> These studies have shown the type and incidence of somatic mutations contributing to dysfunctional signaling pathways in MDSs, as well as their association with disease prognosis and responsiveness to certain drugs. In addition, data are emerging demonstrating immune-related mechanisms that inhibit the body's ability to delete the malignant clones in MDSs.<sup>12</sup>

Given this critical new knowledge, a large variety of biospecific agents targeting these pathogenetic mechanisms in MDS are currently being evaluated in clinical trials. Encouraging results from these investigational studies are emerging, demonstrating the potential for using such agents that focus



**Figure 1. Molecular targets and therapeutics in MDS.** The heterogeneity of molecular abnormalities extant within the MDS spectrum of disorders, involving a variety of somatically mutated genes and biologic functions, is demonstrated along with therapeutic agents in clinical trials focused on targeting these lesions.

on targeting specific disease mechanisms to treat this group of disorders. This article will review the current state of treatment options for MDS patients using these novel agents.

## Molecular genetic landscape of MDSs

More than 45 recurrently mutated pathogenic somatic genes have been identified in MDSs that are involved in a variety of functional categories, including histone modification, DNA repair, epigenetic regulation, RNA splicing, transcription, chromatin remodeling, and kinase signaling networks<sup>13</sup> (Figure 1).

At the time of diagnosis, most cases of MDS are genomically complex, with many clones containing multiple cooperating mutations that can contribute to disease progression and/or relapse, although hematopoiesis is generally dominated by a specific clone.<sup>14</sup> With the widespread adoption of targeted sequencing panels, it is now recognized that >80% of MDS patients harbor  $\geq 1$  known recurrently mutated gene.<sup>11</sup> However, a given recurrent mutation is found in only a small proportion (~10%) of the patients, for which  $\geq 25$  genes have prognostic implications. Frequently complementary mutations cooccur. However, certain mutations are noted to be largely mutually exclusive of one another (eg, the spliceosome genes).<sup>15</sup> Single-cell sequencing studies of myeloid neoplasms are suggesting even more complex clonal architectures, as would have been predicted from bulk sequencing studies alone, with implications for disease monitoring and identification of treatment-resistant clones.<sup>16</sup>

The mutational dynamics of MDSs includes potential for change in clonal dominance with temporal evolution of the patients' specific mutations. Through serial monitoring of mutational status using next-generation sequencing (NGS), clonal evolution of MDSs can be

followed over time. Administration of disease-altering therapy acts as a selective pressure to potentially skew the relative proportions of existing clones and leads to emergence of new clones associated with treatment resistance. In the following sections, we will review the evolving understanding of the recurrently mutated intracellular functional pathways that are frequently implicated in MDSs and novel therapies targeting these molecular defects. In addition, drugs capable of modifying potentially toxic marrow microenvironmental influences for erythropoiesis will be discussed (Table 1).

## DNA maintenance and repair abnormalities

Maintaining the fidelity of the genome is critical for proper eukaryotic cell function. DNA damage can result from endogenous cellular processes or exogenous insults, such as cytotoxic chemotherapy and radiation. DNA double-strand breaks (DSBs) are 1 of the most threatening forms of genomic damage and are repaired by homologous recombination (HR) and nonhomologous end-joining (NHEJ).<sup>17</sup> HR is the preferred cellular DNA repair process because it utilizes homologous DNA, typically from the sister chromatid, as a template for repair. Alternative pathways, such as NHEJ, repair DSBs in a crude fashion by joining broken DNA ends without effective error-suppression mechanisms. Any deficiency in HR leads to increased reliance on error-prone pathways like NHEJ and the introduction of mutagenic deletions and insertions.<sup>18</sup>

MDS pathogenesis is a complex process that involves multiple steps through a sequence leading to accumulation of genetic lesions in the DNA that alter cellular functions engendering emergence of premalignant clones. DSBs are the most severe type of DNA damage, which when not repaired can lead to chromosomal instability and emergence of chromosomal

**Table 1. Molecular subtypes of MDSs and relevant targeted compounds in development**

Molecular subtype	Potential therapeutic compound	Mechanism of action	Phase	Route	Ongoing/recent trials	References
<b>DNA maintenance and repair</b>						
HRD mutations and altered expression	Olaparib, talazoparib, veliparib, temozolomide	Synthetic lethality in absence of functional HRD	1/2	Oral	Decitabine + talazoparib for untreated or R/R AML	NCT02878785
<b>Telomerase dysfunction</b>						
Telomerase overexpression	Imetelstat	Telomerase inhibitor	2/3	IV	Imetelstat for ESA-resistant LR MDS (IMerge)	NCT02986661 <sup>32</sup>
<b>Defective apoptosis</b>						
TP53 mutations or MDMX/MDM2 alterations	ALRN-6924	Targets p53 through MDMX/MDM2 antagonism	1	IV	ALRN-6924 alone or with AraC for AML/MDS	NCT02909972
	Decitabine, 10-d course	DNMT inhibitor	2	IV	Decitabine for HR MDS/AML	105
	APR-246	Refolds/restores wild-type p53	1/2	IV	APR-246 + azacitidine for mutated TP53 MDS	NCT03072043
BCL-2 overexpression	Venetoclax	Decreases BCL-2 expression, proapoptotic	1b	Oral	Venetoclax + azacitidine for untreated HR MDS	NCT02942290
<b>Epigenetic abnormalities</b>						
IDH1/2 mutations	Ivosidenib (AG-120)	Inhibits mutant IDH1	1	Oral	Ivosidenib for mutated IDH1 MDS/AML	59
	Erasidenib (AG-221)	Inhibits mutant IDH2	2	Oral	Denasidenib alone or with azacitidine for mutated IDH2 HR MDS	58
DNMT3A, TET2, ASXL1 mutations	5-Azacitidine	DNMT inhibitor	2	Oral	Azacitidine alone or with davalumab in HMA R/R MDS	NCT03019003
	ASTX727 decitabine w/CDA inhibitor	DNMT inhibitor	2	Oral	ASTX727 vs decitabine (IV) for Int/HR MDS, CMML	NCT03306264
	Guadecitabine (SGI-110)	DNMT inhibitor	3	SC	Guadecitabine vs treatment of choice for HMA R/R MDS	NCT02907359
HDAC abnormalities	Mocetinostat	HDAC inhibitor	1/2	Oral	Mocetinostat + azacitidine for HR MDS	NCT02018926 <sup>108</sup>
	Pracinostat	HDAC inhibitor	2	Oral	Pracinostat + azacitidine for HR MDS	NCT01873703 <sup>62</sup>
	Vorinostat	HDAC inhibitor	2/3	Oral	Azacitidine + vorinostat vs lenalidomide for HR MDS	NCT01522976 <sup>60</sup>
	Eritinostat	HDAC inhibitor	3	Oral	Azacitidine + eritinostat vs azacitidine for MDS and AML	107
<b>Abnormal signal transduction</b>						
CK1 $\alpha$	Lenalidomide	Degradation in del(5q) of CK1 $\alpha$ by E3 ubiquitin ligase cereblon	3	Oral	lenalidomide vs placebo for LR del(5q)	78
Pim kinase/PLK-1	LGH447	Pan-PIM kinase inhibition	1	Oral	LGH447 for R/R HR MDS, AML	NCT02078609
MEK1/2	Volasertib	PLK-1 inhibitor	1	IV	Volasertib for untreated HR MDS	NCT01957644
	Brimetinib (MEK162)	MEK, Ras inhibition	1b	Oral	Brimetinib with or without BYL719 (PI3K inhibitor) for HR MDS	NCT01449058
Ras mutations	Rigosertib	Inhibition of PI3K/AKT pathway and cell cycle checkpoint proteins	3	IV	Rigosertib vs placebo for R/R HR MDS (INSPIRE trial)	NCT01926587
			2	Oral	Rigosertib + azacitidine for untreated HR MDS	
Hedgehog pathway	Sonidegib (erismodegib)	Inhibits Hh signaling	1b	Oral	Sonidegib + azacitidine in R/R HR MDS	NCT02129101

BCL-2, B-cell lymphoma 2; CDA, cytidine deaminase; CK1 $\alpha$ , casein kinase 1 $\alpha$ ; CMML, chronic myelomonocytic leukemia; DNMT, DNA methyl transferase; ESA, erythropoietic agent; GDF-11, growth and differentiation factor-11; HDAC, histone deacetylase; Int, intermediate; LR, lower risk; MDS-RS, MDS with ring sideroblasts; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PI3K, phosphatidylinositol 3-kinase; PLK-1, polo-like kinase 1; R/R, refractory relapsed; SC, subcutaneously; TGF- $\beta$ , transforming growth factor  $\beta$ .

**Table 1. (continued)**

Molecular subtype	Potential therapeutic compound	Mechanism of action	Phase	Route	Ongoing/recent trials	References
BET pathway	Mivebresib (ABBV-075)	Disrupts chromatin remodeling, Myc inhibitor	1	Oral	Mivebresib in subjects with cancer, including AML/MDS	NCT02391480
<b>Spliceosome dysregulation</b>						
SF3B1, U2AF1, SRSF2, ZRSR2 mutations	H3B-8800	Modulator of SF3b complex	1	Oral	H3B-8800 for LR/HR MDS, AML, CMML	NCT02841540
<b>Immune dysregulation</b>						
PD-1/PD-L1 axis	Ipilimumab	CTLA-4 inhibitor	2	IV	Nivolumab + ipilimumab + azacitidine for HR MDS	NCT02530463
	Atezolizumab	PD-L1 inhibitor	1/2	IV	Atezolizumab alone or with azacitidine for R/R MDS	NCT02508870
	Durvalumab	PD-1 inhibitor	2	IV	Durvalumab alone or with oral azacitidine for HMA R/R MDS	NCT02281084
	Pembrolizumab	PD-1 inhibitor	2	IV	Pembrolizumab + azacitidine for HR MDS	NCT03094637
<b>Inhibitory cytokine effects</b>						
TGF- $\beta$ superfamily ligands	Luspatercept	Binds GDF-11	3	SC	Luspatercept for LR MDS-RS, ESA refractory	NCT02631070
	Sotatercept	Binds GDF-11	1/2	SC	Sotatercept for LR MDS	89

BCL-2, B-cell lymphoma 2; CDA, cytidine deaminase; CK1 $\alpha$ , casein kinase 1 $\alpha$ ; CMML, chronic myelomonocytic leukemia; DNMT, DNA methyl transferase; ESA, erythroid-stimulating agent; GDF-11, growth and differentiation factor-11; HDAC, histone deacetylase; Int, intermediate; LR, lower risk; MDS-RS, MDS with ring sideroblasts; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PBK, phosphatidylinositol 3-kinase; PLK-1, polo-like kinase 1; R/R, refractory relapsed; SC, subcutaneously; TGF- $\beta$ , transforming growth factor  $\beta$ .

abnormalities. Investigations have implicated the HR and NHEJ mechanisms as being associated with the susceptibility, pathogenesis, and prognosis of MDSs.<sup>19,20</sup> Recent data have emerged indicating that *IDH1/2* mutations can lead to decreased HR repair and increased sensitivity of MDS cells to poly-ADP ribose polymerase (PARP) inhibitors and other DNA-damaging agents (temozolomide, cisplatin, daunorubicin).<sup>21</sup>

Defects in the HR pathway can be therapeutically exploited by overwhelming already defective DNA-repair mechanisms (platinum salts and alkylators) or by selectively increasing the reliance of tumor cells on alternative error-prone repair pathways.<sup>22,23</sup> Early experience with the PARP inhibitor veliparib in combination with temozolomide showed modest signs of efficacy in a population of refractory or relapsed (R/R) AML or post-MDS patients, with complete remission (CR) rates of 17%. In this study, treatment-induced histone H2AX phosphorylation (a marker of DSBs) was associated with increased response. Most patients who achieved CR in this study had secondary or treatment-related AML in the setting of a prior diagnosis of MDS or chronic myelomonocytic leukemia (CMML).<sup>24</sup> Additional studies of PARP inhibitors alone and in combination with HMAs in MDS are ongoing (Table 1).

## Telomerase dysfunction

Defective maintenance of telomere integrity is a hallmark of cancer and is implicated in MDS pathogenesis. In MDSs, telomere erosion and dysfunction potentiate persistent DNA damage and accumulation of molecular alterations.<sup>25-27</sup> Evidence suggests that telomere erosion can suppress hematopoietic stem cell self-renewal, repopulating capacity, and differentiation.<sup>28,29</sup> Imetelstat is a first-in-class telomerase inhibitor that targets cells with short telomere lengths and highly active telomerase and has been shown in early clinical studies to have activity in myeloid malignancies.<sup>30,31</sup> The role of imetelstat has been explored in MDS patients with low/intermediate-1 scores, based on the International Prognostic Scoring System, and R/R after erythroid-stimulating agents. Data from the first 32 patients in the open-label phase 2 portion of the phase 2/3 IMerge trial showed red blood cell transfusion-independence (TI) rates of 34% and erythroid hematologic improvement of 63% with imetelstat therapy at a median follow-up of 66 weeks.<sup>32</sup> Reversible cytopenias were the most common adverse event. Extension of the IMerge trial is ongoing, randomizing patients to imetelstat vs placebo (NCT02598661).

## TP53 mutation

Mutations in the *TP53* tumor suppressor gene occur at different frequencies in a variety of MDS subsets. *TP53* encodes a DNA-binding transcription factor that induces cell growth arrest, senescence, and cell death by apoptosis upon cellular stress, including oncogenic stress and DNA damage.<sup>33</sup> In hematological malignancies, including MDS, *TP53* mutations confer a poor prognosis and are particularly common in secondary MDS and a portion of patients with del(5q) cytogenetics.<sup>34</sup> PRIMA-1 and the analog APR-246 (PRIMA-1<sup>MET</sup>) restore wild-type conformation of mutant p53 and showed activity in preclinical and early clinical studies, including a 60% response rate (partial response/CR) in p53-mutant ovarian cancer patients in combination with platinum-based chemotherapy.<sup>35,36</sup> A phase 1/2a clinical trial with APR-246 in hematologic malignancies reported no major adverse effects,

with a phase 2 trial in MDS now ongoing.<sup>37</sup> Another approach to reactivate p53-mediated tumor suppression is to inhibit the frequently overexpressed p53 suppressor proteins MDMX and MDM2 in tumors. ALRN-6924, a cell-penetrating stapled  $\alpha$ -helical peptide, disrupts the interaction between p53 and these endogenous inhibitors, thereby reactivating p53-mediated tumor suppression in AML cells.<sup>38</sup> Phase 1/2 clinical testing with this drug is ongoing (Table 1).

## Defective apoptosis

The antiapoptotic protein BCL-2 is overexpressed in hematologic malignancies, where it has been implicated in the maintenance and survival of myeloid cells, therapeutic resistance, and poor clinical outcomes. In a single-arm phase 2 study of the antiapoptotic agent venetoclax, single-agent activity was moderate in a population of R/R patients with refractory myeloid neoplasms ( $n = 32$ ), including 12 (37.5%) patients with MDS. Of note, 33% of patients with isocitrate dehydrogenase 1/2 (IDH1/2) mutations achieved CR in this study, suggesting increased activity in this subgroup.<sup>39</sup> Mutant IDH1/2 proteins alter the epigenetic landscape in AML cells through production of the oncometabolite (R)-2-hydroxyglutarate (2-HG), sensitizing these cells to Bcl-2 inhibition by venetoclax (ABT-199).<sup>40</sup> This sensitization effect is induced by 2-HG-mediated inhibition of the activity of cytochrome c oxidase in the mitochondrial electron transport chain; suppression of cytochrome c oxidase activity lowered the mitochondrial threshold to trigger apoptosis upon BCL-2 inhibition. These findings are potentially valuable for considering the use of Bcl-2 inhibitors in *IDH*-mutated patients.

Marked synergistic activity has also been seen in vitro and in vivo models of BCL-2 inhibition with lower-intensity therapies, such as low-dose cytarabine and HMAs. Phase 1b data have suggested a high degree of clinical activity of these combinations, especially in higher-grade myeloid malignancies, including MDS with excess blasts and AML, with 61% of patients achieving a CR or incomplete CR.<sup>41</sup> The combination of venetoclax with HMAs or low-dose cytarabine has shown encouraging responses in R/R AML and MDS patients.<sup>42</sup> These responses are predominantly evident in the upfront setting. Extensions of these studies are ongoing.

## Epigenetic abnormalities

Aberrant differentiation in MDS is often related to abnormal DNA methylation and mutations in genes that regulate epigenetic programs (*TET2* and *DNMT3a*, involved in DNA methylation control; *EZH2* and *ASXL1*, involved in histone methylation control).<sup>43</sup> This epigenetic nature of MDS may explain the finding that it is a disease most responsive to DNA methylation inhibitors (HMAs). Progression in MDS is characterized by acquisition of further epigenetic defects and mutations in growth-controlling genes that may alter the proliferation/apoptosis balance, thus contributing to the development of AML.

Azanucleosides, pyrimidine analogs of the nucleoside cytidine, are potent inhibitors of DNA methyl transferase and are referred to as HMAs. As indicated above, the azanucleosides now used clinically are 5-azacitidine and 5-aza-2'-deoxycytidine (decitabine). Parenteral formulations of azacitidine and decitabine remain the only FDA-approved HMA agents available for the treatment of MDS. Interest in oral formulations of HMA therapy has been increasing, for patient-related logistical reasons and based on preclinical data suggesting

that extended dosing associated with increased drug exposure to leukemic cells was beneficial. Multiple such HMAs are in various stages of clinical development. Oral azacitidine (CC-486) has been evaluated in a phase 1/2 study in hematologic malignancies, showing good tolerability and overall response rates (ORRs) of 36% (14-day schedule) and 41% (21-day schedule) in lower-risk (LR) MDSs.<sup>44</sup> CC-486 is being evaluated in a phase 3 randomized double-blind placebo-controlled LR MDS therapy trial (AZA-MDS-003).

Guadecitabine (SGI-110) is a small dinucleotide composed of decitabine and deoxyguanosine. Deoxyguanosine prevents deamination of decitabine, prolonging in vivo exposure of cells to the drug. Phase 2 data in HR MDS, CMML, and low blast count AML patients R/R after HMA therapy showed a modest salvage response rate.<sup>45</sup> Another oral decitabine combination (ASTX727), includes the cytidine deaminase inhibitor cedazuridine plus decitabine. In a recent phase 1/2 trial, effective in vivo levels of the drug combination were achieved, with a good ORR.<sup>46</sup> Although these new agents are not mechanistically novel, their oral potency provides potential logistic advantages for drug usage.

## IDH1/2 dysregulation

Dysregulation of cellular metabolism has recently become an accepted "hallmark" of cancer.<sup>47</sup> The IDH family of isozymes (IDH1, IDH2, IDH3) normally functions to convert isocitrate to  $\alpha$ -ketoglutarate via oxidative decarboxylation.<sup>48</sup> Mutations in *IDH1* and *IDH2* were initially described in gliomas, with elegant work showing that these mutations were always heterozygous, with resulting neomorphic activity causing conversion of  $\alpha$ -ketoglutarate to the oncometabolite 2-HG.<sup>49,50</sup> Elevated 2-HG levels alter epigenetic regulation and block cellular differentiation, thereby promoting tumor development.<sup>51</sup>

*IDH1* and *IDH2* mutations occur in ~20% of de novo AML,<sup>52</sup> with a lower frequency of 5% to 12% in MDS.<sup>53-55</sup> As in AML, *IDH1/2* mutations in MDS patients appear to be associated with older age, higher platelet counts, normal karyotype, and comutations in *DNMT3A*, *ASXL1*, and *SRSF2*.<sup>54</sup> Additionally, *IDH1* and *IDH2* mutations appear to be mutually exclusive to each other and to *TET2*.<sup>54</sup> Prognostic implications of *IDH1/2* mutations in MDS remain controversial but appear to have an overall negative impact, especially in LR disease.<sup>53,55-57</sup>

A better understanding of the pathophysiology of *IDH1/2* mutations in MDS and AML have led to development of clinical IDH1 and IDH2 inhibitors (Table 1). Enasidenib (AG-221) is a covalent inhibitor of IDH2 and was the first approved compound for treatment of R/R AML with *IDH2* mutations, based on the AG221-C-001 study, an open-label single-arm multicenter study including 199 adults with a demonstrable *IDH2* mutation. In this study, patients with R/R AML were treated with a daily oral dose of enasidenib. After a median follow-up of 6.6 months, 23% of patients experienced CR or incomplete CR lasting a median of 8.2 months. Of the 157 patients initially dependent on red blood cell transfusion, 34% achieved TI, with 76% of these patients maintaining prolonged TI status.<sup>58</sup> Differentiation syndrome occurred in 14% of patients. A decrease in *IDH2* variant allele frequency was not associated with CR, suggesting that enasidenib promoted differentiation and did not necessarily have cytotoxic effects. In a subset of 15 MDS patients included in the original phase 1 trials, ORR was 53%, although no mutational signature was predictive of response. Ongoing studies of enasidenib

in MDS include a phase 2 trial examining the role of enasidenib alone or combined with azacitidine for an HMA R/R cohort in HMA-naive patients. Additional studies with the *IDH1* inhibitor AG-120 (ivosidenib) have generated similar results, with phase 1 data in R/R AML showing a 42% ORR and 22% CRs, with a median response duration of 8.2 months.<sup>59</sup> However, persistence of the IDH mutations occurred in ~80% of those with CRs, suggesting differentiation as the primary mechanism of action. Importantly, no co-occurring mutations predicted clinical response or resistance to therapy. Similar studies are ongoing for HR MDS.

## Deregulated histone deacetylases

Histone acetylation facilitates active gene transcription that is highly regulated by histone deacetylases (HDACs). HDAC inhibition can restore normal acetylation of deregulated histone proteins and transcription factors. Given the potential biologic synergy of HDAC inhibitors with HMAs, vorinostat, a small molecule inhibitor of class I and II HDAC enzymes, was combined with azacitidine in encouraging phase 1 and 2 studies for HR MDS. However, a large randomized phase 3 study evaluating the impact of azacitidine plus vorinostat vs azacitidine alone in HR MDS and CMML patients demonstrated that the ORR between these groups was similar, as were remission duration and overall survival (OS).<sup>60</sup> Of interest, in a subgroup analysis, ORR was higher in patients with the epigenetically dysregulated *DNMT3A* mutations. Additional HDAC inhibitors have been developed to determine whether other classes of these agents could be beneficially applied. However, studies with entinostat<sup>61</sup> and pracinostat<sup>62</sup> have similarly shown no clinical benefit when combined with azacitidine compared with azacitidine alone. Despite early positive findings, the randomized trials indicated the potential challenges in trial design and potential toxicities for use of this drug combination, particularly because suboptimal combinations of overlapping, rather than sequential, HDAC/HMA, were utilized.<sup>63-65</sup>

## Abnormal signal transduction

Abnormalities in signal-transduction pathways involved in the pathogenesis and progression of a wide variety of neoplasias have been demonstrated in MDSs, including those for the serine/threonine kinase AKT, which functions as a critical mediator of signaling downstream of phosphatidylinositol 3-kinase (PI3K),<sup>66,67</sup> PKC $\alpha$ ,<sup>68</sup> the mammalian target of rapamycin,<sup>69</sup> aurora kinases,<sup>70</sup> cyclin D1,<sup>71</sup> and casein kinase (CK1 $\alpha$ ).<sup>72</sup>

Given these findings, several kinase inhibitors have been used to treat MDS patients. The small molecule compound rigosertib binds to the Ras-binding domain of multiple kinases, including RAF, PI3K, and other effectors of Ras-related GTPases, and induces inhibition of the PI3K and polo-like kinase pathways.<sup>67,73-76</sup> In a phase 3 trial that randomized 299 MDS patients to rigosertib vs best supportive care (BSC), although the median OS in the rigosertib group was not significantly longer than in the control group, in a preplanned exploratory analysis, patients with primary HMA failure treated with rigosertib had a trend toward longer median OS (8.6 vs 5.3 months).<sup>76</sup> Additionally, in a post hoc analysis of patients with very high risk status based on the revised International Prognostic Scoring System, improved survival was noted in the rigosertib group compared with the BSC group (median OS, 7.6 vs 3.2 months).

A randomized phase 3 trial of rigosertib vs BSC (NCT02562443) is underway in this HR population to attempt to confirm the potential role of this agent.

Another kinase abnormality implicated in these patients relates to the findings in the MDS del(5q) subtype. Although the mechanisms underlying the anemia in these patients remain elusive, haploinsufficiency and dependence of the erythroid cells on CK1 $\alpha$  (a gene within the common deleted region of del(5q) MDS) appear to be of central importance. Lenalidomide induces ubiquitination of CK1 $\alpha$  by the E3 ubiquitin ligase cereblon, resulting in CK1 $\alpha$  degradation.<sup>72</sup> Such degradation in the haploinsufficient del(5q) cells sensitized these cells to lenalidomide therapy, providing a basis for the therapeutic effects of the drug in these patients. The E3 ubiquitin ligase RNF41 is a principal target that is responsible for erythropoietin receptor stabilization. Data have indicated that lenalidomide also has E3 ubiquitin ligase inhibitory effects that inhibit RNF41 autoubiquitination and promote membrane accumulation of signaling-competent JAK2/EpoR complexes that augment erythropoietin responsiveness.<sup>77</sup> An initial phase 2 trial showed particular (~65%) responsiveness of MDS patients with the del(5q31) chromosomal abnormality to lenalidomide, demonstrating a major reduction in transfusion requirements and reversal of cytologic and cytogenetic abnormalities in this subset of patients.<sup>4</sup> Reduced, although meaningful responses, were also seen in non-del(5q) patients in phase 2 and randomized phase 3 trials.<sup>5,78</sup> The negative impact of *TP53* mutations on responsiveness and outcome postlenalidomide is notable for ~30% of these patients.<sup>79</sup>

## Spliceosome dysregulation

Alternative splicing of messenger RNA (mRNA) precursors is a critical cellular process common to most eukaryotic genomes. The spliceosome is a large ribonuclear-protein complex located in the cell nucleus that is composed of 5 small nuclear ribonucleoproteins and >200 polypeptides.<sup>80</sup> Sequencing studies have indicated that spliceosome mutations are very frequent in MDS, with upward of 45% to 60% of patients having somatic mutations affecting a component of the spliceosome.<sup>9,81</sup> Mutations are typically heterozygous single nucleotide polymorphisms that localize to well-characterized hotspot regions of *SF3B1*, *SRSF2*, *U2AF1*, *ZRSR2*, *PRPF40B*, *SF3A1*, *SF1*, and *U2AF65*. When mutated, normal intronic splicing cannot occur efficiently, leading to intron retention and introduction of stop codons, rendering pre-mRNA susceptible to non-sense-mediated decay.<sup>82</sup>

Animal models have suggested a critical role for splicing mutations in the development of myeloid neoplasms. Work with the mouse model of inducible *SRSF2 P95H* and *U2AF1 S34F* mutations suggested that development of MDS is due, in part, to splicing alterations leading to ineffective hematopoiesis.<sup>9,83</sup> Further investigations evaluating large unbiased screens of small molecules with antitumor properties uncovered a class of compounds capable of binding with high affinity to the 3' splice site, destabilizing U2 small nuclear ribonucleoprotein/pre-mRNA complexes and preventing spliceosome assembly. Further refinement of these molecules caused their increased stability and activity leading to development of sudemycin, spliceostatin A, meayamycin, E7107, and, most recently, H3B-8800.

In *SRSF2 p95H*-transgenic mice, E7107 resulted in reduced disease burden.<sup>84</sup> Based on these results, E7107 entered phase 1 studies in patients with advanced solid tumors. Single-agent antitumor activity was observed, and corollary studies showed pre-mRNA splicing modulation in peripheral blood mononuclear cells, suggesting on-target activity. However, the unanticipated side effect of visual loss in 2 participants secondary to optic neuritis necessitated discontinuation of the trial.<sup>85</sup> Preclinical models indicated that splicing modulators are selectively lethal to tumor cells via the mechanism of synthetic lethality.<sup>86</sup> The only splice gene modulator compound in active clinical trials is H3B-8800, an orally available selective small molecule SF3B1 modulator. The compound is being evaluated in LR and HR MDS, CMML, and AML in a phase 1/2 open-label multicenter study (Table 1). Cohorts with canonical splicing mutations and wild-type patients are being evaluated for safety. Should safety data be favorable, the trial will continue to an expansion phase that will enroll cohorts enriched for patients with splicing mutations.

## Inhibitory cytokine effects

Increased levels of the transforming growth factor  $\beta$  superfamily inhibitors of erythropoiesis (predominantly growth and differentiation factor-11) occur within MDS erythroid cells. Luspatercept (ACE-536) is a novel fusion protein that acts as a ligand trap and binds to and blocks this inhibitory factor's Smad2/3 signaling, thus increasing erythropoiesis.<sup>87</sup> Encouraging phase 2 data, with good drug tolerance, have been shown in LR MDS patients who are nonresponsive to erythroid-stimulating agents, predominantly those with ring sideroblasts. These patients demonstrated an ~60% erythroid response rate compared with ~25% for those lacking this feature.<sup>88</sup> A phase 3 randomized trial with luspatercept is currently completing analysis (NCT02631070). Similar phase 2 results, although with somewhat increased toxicity, have been reported for the chemically related compound sotatercept in the treatment of LR MDS.<sup>89</sup>

## Immune dysregulation

Immunologic tolerance to cancer has major implications for the ability of tumors to survive, despite a variety of therapeutic approaches. A critical mechanism underlying this microenvironmental dysfunction relates to the ability of tumor cells to block immune checkpoints through expression of specific proteins that interfere with immune cell effector function. Expression of the lymphoid transmembrane PD-1 after T-cell activation is a normal physiological checkpoint that the immune system utilizes to avoid self-reactive T cells.<sup>90</sup> However, tumor cells, through their generation and overexpression of ligands for PD-1 (eg, PD-L1 and PD-L2), exploit this pathway directly through expression of PD-L1/PD-L2 or indirectly by recruiting regulatory T cells that express PD-L1, causing immune dysfunction.<sup>91-93</sup> Recent clinical trials have used a number of checkpoint inhibitors to treat solid and lymphoid tumors with variable degrees of efficacy.<sup>91</sup>

Such approaches have recently been applied to myeloid malignancies. Phase 1 trials for treating MDS have been reported with several checkpoint inhibitors as targets, either alone or in combination with azacitidine. The combination has been used because HMAs increase the levels of checkpoint inhibitors.<sup>12,94</sup>

The agents, predominantly used in HMA-resistant disease, were pembrolizumab (PD-1 inhibitor), nivolumab (PD-1 inhibitor), and ipilimumab (CTLA-4 inhibitor). Pembrolizumab alone was used mainly for LR patients, whereas nivolumab and ipilimumab were used alone or with azacitidine for HR patients.<sup>95</sup> These trials demonstrated generally low hematologic responses but tolerable safety profiles.<sup>44,96</sup> A phase 1b/2 randomized trial of atezolizumab, alone or with azacitidine, for HMA R/R or naive MDS patients is ongoing (NCT02508870).

## Personalized therapy selection in MDS

As discussed in this review, in recent years the previously homogeneous clinical view of MDS has been supplanted by heterogeneous groupings defined by disease-related cytogenetic and molecular alterations. Despite our increasing molecular understanding of disease, response rates remain suboptimal (CR < 20%), even in molecularly predefined subgroups of patients treated with some of the novel agents. Beyond the compounds discussed above, multiple drugs targeting various dysregulated pathways within MDS patients have FDA approvals for other indications. However, despite advances in solid tumor and AML trial design, matching patients by genetic signature to targeted therapies (so-called “basket and umbrella trials”), such strategies have not had widespread adoption in MDS. Recently, 2 complementary strategies have emerged for potentially improving patient stratification in myeloid malignancies: *ex vivo* drug response profiling and *in silico* predictive simulation modeling. Increasing data suggest that such approaches may be useful in clinical personalized therapy selection for MDS patients.

### Overview of *in silico* testing

*In silico* predictive simulation is a rapidly emerging technique for the modeling of a digital library of molecular targeted drugs on a cell signaling model informed by an individual tumor's molecular and cytogenetic abnormalities. Using computer-simulated approaches, these techniques determine whether the patient's gene mutations result in activated or inactivated proteins and then whether the protein is overexpressed or underexpressed, by utilizing information derived from the patient's cytogenetics and/or chromosome copy number variation data. Protein network maps of each patient's mutome depict the interactive nature of all predicted aberrant protein signaling pathways.<sup>97</sup>

Recently reported data have shown the ability of this technology to predict treatment response in MDS patients receiving azacitidine, decitabine, venetoclax, and lenalidomide.<sup>97-99</sup> In 1 cohort of 46 del(5q) MDS patients, the *in silico* approach predicted responses to lenalidomide treatment in 80% of patients.<sup>97</sup> These studies have demonstrated that a computational biology technology is able to detail the complexity of the MDS signaling networks to simulate and predict drug response. Further studies are ongoing utilizing such approaches as a clinical decision support tool.

### Overview of *ex vivo* testing

*Ex vivo* chemosensitivity assays have been used in the study of myeloid neoplasms for >30 years. These assays use incubation of viable patient-derived mononuclear myeloid cells with various chemotherapeutic compounds, with efficacy of

response measured by a variety of direct or indirect measures of cell viability, cell cycle arrest, or apoptosis. However, clinical implementation of these assays has been limited by lack of standardization, difficulty with automation, operator-dependent biases, difficulty maintaining living cells in culture, and slow turnaround time. Newer fully automated techniques, utilizing flow cytometric readouts, have begun to overcome many prior limitations.<sup>98,100-102</sup>

Preliminary correlative studies have suggested the ability of such testing to predict clinical response to chemotherapeutic agents. Techniques have been applied to primary MDS patient samples, with resulting *ex vivo* results identifying novel subgroups of MDS with unique drug-sensitivity patterns correlating with clinical responses.<sup>103</sup> Additionally, this type of approach has recently been prospectively studied in patients with refractory AML using

an *ex vivo* drug-sensitivity testing (DST) platform. The study showed treatment response and survival benefit of DST-guided therapy compared with patients treated according to non-DST recommendations.<sup>104</sup>

## Authorship

Contribution: A.A. and P.L.G. designed and performed the research, analyzed the data, and wrote the manuscript.

Conflict-of-interest disclosure: P.L.G. receives research funds from H3 Biotech, Genentech, Notable Labs, and Celgene; and is a consultant to Novartis. A.A. is a consultant to Mission Bio Inc.

Correspondence: Peter L. Greenberg, Stanford University Cancer Center, 875 Blake Wilbur Dr, #2335, Stanford, CA 94305-5821; e-mail: peterg@stanford.edu.

## References

1. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood*. 2012;120(12):2454-2465.
2. Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). *Leukemia*. 2015;29(7):1502-1513.
3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009;10(3):223-232.
4. List A, Dewald G, Bennett J, et al; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. *N Engl J Med*. 2006;355(14):1456-1465.
5. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. *Blood*. 2008;111(1):86-93.
6. Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. *Cancer*. 2007;109(2):265-273.
7. Bejar R, Greenberg PL. The Impact of somatic and germline mutations in myelodysplastic syndromes and related disorders. *J Natl Compr Canc Netw*. 2017;15(1):131-135.
8. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. *N Engl J Med*. 2011;364(26):2496-2506.
9. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. *Nature*. 2011;478(7367):64-69.
10. Papaemmanuil E, Gerstung M, Malcovati L, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood*. 2013;122(22):3616-3627, quiz 3699.
11. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. *Leukemia*. 2014;28(2):241-247.
12. Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. *Leukemia*. 2014;28(6):1280-1288.
13. Lee E, Podoltsev N, Gore SD, Zeidan AM. The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. *Blood Rev*. 2016;30(1):1-10.
14. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. *Cell*. 2012;150(2):264-278.
15. Gerstung M, Pellagatti A, Malcovati L, et al. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. *Nat Commun*. 2015;6(1):5901.
16. Aleshin A, Greenberg P, Medeiros B, et al. Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression [abstract]. *Cancer Res*. 2018;78(13 suppl). Abstract 3004.
17. Mehta A, Haber JE. Sources of DNA double-strand breaks and models of recombinational DNA repair. *Cold Spring Harb Perspect Biol*. 2014;6(9):a016428.
18. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. *Annu Rev Biochem*. 2008;77(1):229-257.
19. Ribeiro HL Jr, Maia ARS, de Oliveira RTG, et al. DNA repair gene expressions are related to bone marrow cellularity in myelodysplastic syndrome. *J Clin Pathol*. 2017;70(11):970-980.
20. Valka J, Vesela J, Votavova H, et al. Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome. *Eur J Haematol*. 2017;99(4):323-331.



21. Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. *Sci Transl Med.* 2017;9(375):eaal2463.
22. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. *Nat Rev Cancer.* 2004;4(10):814-819.
23. Lord CJ, Ashworth A. BRCAness revisited. *Nat Rev Cancer.* 2016;16(2):110-120.
24. Gojo I, Beumer JH, Pratz KW, et al. A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. *Clin Cancer Res.* 2017;23(3):697-706.
25. Rudolph KL, Chang S, Lee HW, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. *Cell.* 1999;96(5):701-712.
26. Karlseder J, Smogorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss. *Science.* 2002;295(5564):2446-2449.
27. d'Adda di Fagnana F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. *Nature* 2003;426(6963):194-198.
28. Wang J, Sun Q, Morita Y, et al. A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage [published correction appears in *Cell.* 2014;158(6):1444]. *Cell.* 2012;148(5):1001-1014.
29. Rossi DJ, Bryder D, Seita J, Nussenzweig A, Hoeijmakers J, Weissman IL. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. *Nature.* 2007;447(7145):725-729.
30. Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. *N Engl J Med.* 2015;373(10):908-919.
31. Zhao X, Tian X, Kajigaya S, et al. Epigenetic landscape of the *TERT* promoter: a potential biomarker for high risk AML/MDS. *Br J Haematol.* 2016;175(3):427-439.
32. Fenaux P, Raza A, Vellenga E, et al. Imetelstat in RBC transfusion-dependent lower risk MDS relapsed/refractory to erythropoiesis-stimulating agents (IMerge): updated efficacy and safety. Paper presented at the 23rd Congress of the European Haematology Association. 17 June 2018. Stockholm, Sweden.
33. Vousden KH, Lu X. Live or let die: the cell's response to p53. *Nat Rev Cancer.* 2002;2(8):594-604.
34. Kulasekararaj AG, Smith AE, Mian SA, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. *Br J Haematol.* 2013;160(5):660-672.
35. Gourley C, Green J, Gabra H, et al. PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC). *J Clin Oncol.* 2016;34(15 suppl):5571.
36. Peng X, Zhang M-Q-Z, Conserva F, et al. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase [published correction appears in *Cell Death Dis.* 2017;8(4):e2751]. *Cell Death Dis.* 2013;4(10):e881.
37. Deneberg S, Cherif H, Lazarevic V, et al. An open-label phase I dose-finding study of APR-246 in hematological malignancies. *Blood Cancer J.* 2016;6(7):e447.
38. Carvajal LA, Ben-Neriah D, Senecal A, et al. Dual inhibition of Mdmx and Mdm2 using an alpha-helical P53 stapled peptide (ALRN-6924) as a novel therapeutic strategy in acute myeloid leukemia. *Blood.* 2017;130(suppl 1):795.
39. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a Phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. *Cancer Discov.* 2016;6(10):1106-1117.
40. Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. *Nat Med.* 2015;21(2):178-184.
41. DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. *Lancet Oncol.* 2018;19(2):216-228.
42. DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. *Am J Hematol.* 2018;93(3):401-407.
43. Issa J-PJ. The myelodysplastic syndrome as a prototypical epigenetic disease. *Blood.* 2013;121(19):3811-3817.
44. Garcia-Manero G, Gore SD, Kambhampati S, et al. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. *Leukemia.* 2016;30(4):889-896.
45. Sebert M, Bally C, Peterlin P, et al. Results of a phase II study of guadecitabine (SGI-110) in higher risk MDS, CMML or low blast count AML patients refractory to or relapsing after azacitidine (AZA) treatment. *Blood.* 2016;128(22):347.
46. Garcia-Manero G, Griffiths EARG. A phase 2 dose-confirmation study of oral ASTX727, a combination of oral decitabine with a cytidine deaminase inhibitor (CDAi) cedazuridine (E7727), in subjects with myelodysplastic syndromes (MDS). *Blood* 2017;130 (suppl 1):4274.
47. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011;144(5):646-674.
48. Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. *Ann Oncol.* 2016;27(4):599-608.
49. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature.* 2009;462(7274):739-744.
50. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell.* 2010;17(3):225-234.
51. Clark O, Yen K, Mellinghoff IK. Molecular pathways: isocitrate dehydrogenase mutations in cancer. *Clin Cancer Res.* 2016;22(8):1837-1842.
52. Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia [published correction appears in *N Engl J Med.* 2013;369(1):98]. *N Engl J Med.* 2013;368(22):2059-2074.

53. Lin C-C, Hou H-A, Chou W-C, et al. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. *Am J Hematol*. 2014;89(2):137-144.
54. DiNardo CD, Jabbour E, Ravandi F, et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. *Leukemia*. 2016;30(4):980-984.
55. Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. *Haematologica*. 2010;95(10):1668-1674.
56. Jin J, Hu C, Yu M, et al. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. *PLoS One*. 2014;9(6):e100206.
57. Bejar R, Papaemmanuil E, Haferlach T, et al. Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the International Working Group for Prognosis in MDS-Molecular Committee. *Blood*. 2015;126(23):907.
58. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant *IDH2* relapsed or refractory acute myeloid leukemia. *Blood*. 2017;130(6):722-731.
59. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in *IDH1*-mutated relapsed or refractory AML. *N Engl J Med*. 2018;378(25):2386-2398.
60. Sekeres MA, Othus M, List AF, et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American intergroup study swog s1117. *J Clin Oncol*. 2017;35(24):2745-2753.
61. Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. *J Clin Oncol*. 2014;32(12):1242-1248.
62. Garcia-Manero G, Montalban-Bravo G, Berdeja JG, et al. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. *Cancer*. 2017;123(6):994-1002.
63. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. *Blood*. 2009;114(13):2764-2773.
64. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. *Cancer Res*. 2006;66(12):6361-6369.
65. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. *Nat Genet*. 1999;21(1):103-107.
66. Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K, Yamada O. The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. *Anticancer Agents Med Chem*. 2009;9(5):550-559.
67. Seetharam M, Fan AC, Tran M, et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. *Leuk Res*. 2012;36(1):98-103.
68. Poli A, Ratti S, Finelli C, et al. Nuclear translocation of PKC- $\alpha$  is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs). *FASEB J*. 2018;32(2):681-692.
69. Follo MY, Mongiorgi S, Bosi C, et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. *Cancer Res*. 2007;67(9):4287-4294.
70. Borges DP, Dos Santos AWA, Paier CRK, et al. Prognostic importance of aurora kinases and mitotic spindle genes transcript levels in myelodysplastic syndrome. *Leuk Res*. 2018;64:61-70.
71. Olnes MJ, Shenoy A, Weinstein B, et al. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. *Leuk Res*. 2012;36(8):982-989.
72. Krönke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1 $\alpha$  in del(5q) MDS. *Nature*. 2015;523(7559):183-188.
73. Chun AW, Cosenza SC, Taft DR, Maniar M. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. *Cancer Chemother Pharmacol*. 2009;65(1):177-186.
74. Prasad A, Park I-W, Allen H, et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. *Oncogene*. 2009;28(12):1518-1528.
75. Gumireddy K, Reddy MVR, Cosenza SC, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent [published correction appears in *Cancer Cell*. 2005;7(5):497]. *Cancer Cell*. 2005;7(3):275-286.
76. Garcia-Manero G, Fenaux P, Al-Kali A, et al; ONTIME study investigators. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. *Lancet Oncol*. 2016;17(4):496-508.
77. Basiorka AA, McGraw KL, De Ceuninck L, et al. Lenalidomide stabilizes the erythropoietin receptor by inhibiting the E3 ubiquitin ligase RNF41. *Cancer Res*. 2016;76(12):3531-3540.
78. Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. *J Clin Oncol*. 2016;34(25):2988-2996.
79. Mossner M, Jann J-C, Nowak D, et al. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the German MDS Study Group (GMDS). *Leukemia*. 2016;30(9):1956-1959.

80. Will CL, Lührmann R. Spliceosome structure and function. *Cold Spring Harb Perspect Biol.* 2011;3(7):a003707.
81. Inoue D, Bradley RK, Abdel-Wahab O. Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. *Genes Dev.* 2016;30(9):989-1001.
82. Lee SC-W, Dvinge H, Kim E, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins [published correction appears in *Nat Med.* 2016;22(6):692]. *Nat Med.* 2016;22(6):672-678.
83. Kim E, Ilagan JO, Liang Y, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. *Cancer Cell.* 2015;27(5):617-630.
84. Folco EG, Coil KE, Reed R. The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. *Genes Dev.* 2011;25(5):440-444.
85. Hong DS, Kurzrock R, Naing A, et al. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) spliceosome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. *Invest New Drugs.* 2014;32(3):436-444.
86. Seiler M, Yoshimi A, Darman R, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. *Nat Med.* 2018;24(4):497-504.
87. Suragani RNVS, Cadena SM, Cawley SM, et al. Transforming growth factor- $\beta$  superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. *Nat Med.* 2014;20(4):408-414.
88. Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. *Lancet Oncol.* 2017;18(10):1338-1347.
89. Komrokji R, Garcia-Manero G, Ades L, et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. *Lancet Haematol.* 2018;5(2):e63-e72.
90. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. *Immunol Rev.* 2010;236(1):219-242.
91. Zou W. Regulatory T cells, tumour immunity and immunotherapy. *Nat Rev Immunol.* 2006;6(4):295-307.
92. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med.* 2004;10(9):942-949.
93. Curiel TJ. Tregs and rethinking cancer immunotherapy. *J Clin Invest.* 2007;117(5):1167-1174.
94. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. *Clin Cancer Res.* 2008;14(10):3044-3051.
95. Garcia-Manero G, Tallman MS, Martinelli G, et al. Pembrolizumab, a PD-1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of hypomethylating agent treatment. *Blood.* 2016;128(22):345.
96. Garcia-Manero G, Daver NG, Montalban-Bravo G, et al. A phase II study evaluating the combination of nivolumab (Nivo) or Ipilimumab (Ipi) with azacitidine in Pts with previously treated or untreated myelodysplastic syndromes (MDS). *Blood.* 2016;128(22):344.
97. Drusbosky L, Medina C, Martuscello R, et al. Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. *Leuk Res.* 2017;52:1-7.
98. Drusbosky L, Abbasi T, Vali S, et al. A genomic signature predicting venetoclax treatment response in AML identified by protein network mapping and validated by ex vivo drug sensitivity testing: A Beat AML Project study. *Blood.* 2016;128(22):1723.
99. Drusbosky L, Kumar Singh N, Tiwari P, Vali S, Abbasi TSS. A genomic rule predicting HMA treatment response in MDS identified by protein network mapping and validated by clinical trial simulation. *Blood.* 2016;128(22):3151.
100. Rocchi L, Faenza A, Rambelli L, et al. Ex-vivo drug response profiling for precision medicine approaches in acute myeloid leukemia with the open microwell microfluidic platform. *Blood.* 2016;128(22):1675.
101. Yeung KY, Blau CA, Oehler VG, et al. Personalized approach to treatment of acute myeloid leukemia using a high-throughput chemosensitivity assay. *Blood.* 2013;122(21):483.
102. Prashad SL, Drusbosky L, Sibai H, et al. Ex vivo high-throughput flow cytometry screening identifies subsets of responders to differentiation agents in individual AML patient samples. *Blood.* 2016;128(22):5206.
103. Aleshin A, Medeiros B, Kamble S, et al. Recurrent drug sensitivity patterns in MDS patients are recapitulated by ex vivo drug response profiling [abstract]. *Cancer Res.* 2018;78(13 suppl). Abstract 568.
104. Swords RT, Azzam D, Al-Ali H, et al. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. *Leuk Res.* 2018;64:34-41.
105. Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. *N Engl J Med.* 2016;375(21):2023-2036.
106. Luger SM, O'Connell CL, Klimek V, et al. A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS). *J Clin Oncol.* 2013;31(15 suppl):7116.
107. Prebet T, Sun Z, Ketterling RP, et al; Eastern Cooperative Oncology Group and North American Leukemia intergroup. Azacitidine with or without entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. *Br J Haematol.* 2016;172(3):384-391.